You’ve tried everything for focus — caffeine cycling, lion’s mane, prescription stimulants that leave you wired. Then someone mentioned Semax, a nasal peptide that’s been prescribed in Russia since 2011 for cognitive enhancement and stroke recovery. No injection required. Approved as an actual pharmaceutical, not a supplement or research chemical. That got your attention.

But then you hit the wall: most of the research is published in Russian, the regulatory status in the U.S. is complicated, and the biohacking forums can’t agree on whether it’s a game-changer or placebo. Here’s what the evidence actually shows.

Semax

ACTH 4–10 Analog (Cognitive Nasal Peptide)

Also known as: Met-Glu-His-Phe-Pro-Gly-Pro (ACTH 4–10 analog with C-terminal Pro-Gly-Pro)

Cognitive Performance (primary)Neuroprotection
T2: Emerging EvidenceCognitive enhancement
T2: Emerging EvidenceNeuroprotection
FDA Status:Category 2 — expected to return to Category 1. Not PCAC-referred. Approved pharmaceutical in Russia since 2011.

Evidence Summary

Strongest evidence for:
Cognitive enhancement and attention (Russian clinical use since 2011, human studies on attention and BDNF levels)
Promising but early:
Stroke recovery and neuroprotection (Russian clinical applications)
Mostly anecdotal:
Long-term cognitive optimization in healthy adults
Key limitation:
Most research published in Russian. Limited Western peer-reviewed human data. Approved in Russia but no FDA pathway in the U.S.

What It Is

Semax is a synthetic peptide derived from ACTH (adrenocorticotropic hormone), specifically the 4–10 fragment with an added Pro-Gly-Pro tail for stability. It modulates dopamine and serotonin systems and upregulates BDNF (brain-derived neurotrophic factor) — the protein responsible for neuroplasticity and new neural connections. Administered as a nasal spray, no injection required. Approved as a pharmaceutical in Russia for cognitive enhancement, stroke recovery, and optic nerve disease.

What the Research Says

Cognitive Enhancement

T2: Emerging Evidence

Russian clinical use since 2011 for attention, memory, and mental performance. Human studies show increased BDNF levels and improved attention metrics. Most research published in Russian journals.

Stroke Recovery

T2: Emerging Evidence

Used clinically in Russia for ischemic stroke. Studies show neuroprotective effects and improved recovery outcomes.

BDNF Upregulation

T2: Emerging Evidence

Documented in human and animal studies. BDNF is a key mediator of neuroplasticity, learning, and memory formation.

Without Western controlled human trials, we can’t fully verify that the practitioner-reported benefits hold up to peer-reviewed scrutiny. The Russian clinical track record is real, but “approved in Russia” is not the same as “proven by Western RCT standards.”

Typical Protocol

RouteNasal spray (no injection)
Dosage Range200–600 mcg/day
Frequency1–2 times daily, typically morning
Cycle Length10–20 days, with breaks
Time to EffectOften noticeable within days
NoteProvider determines protocol. Nasal administration is straightforward but dosing still requires medical guidance.

Protocols vary by individual. Always follow your prescribing provider's instructions.

Risks & Side Effects

  • Generally well-tolerated in Russian clinical use across decades.
  • Nasal irritation — the most commonly reported side effect.
  • Headache — uncommon.
  • Hair shedding reported anecdotally at higher doses.
  • No significant safety signals in decades of Russian pharmaceutical use, but Western safety data is limited.

Who Should Not Consider Semax

If you are on MAOIs or other catecholamine-affecting medications: Semax modulates dopamine and serotonin systems. Combining it with MAOIs or other medications that affect catecholamine levels has not been studied and creates an unpredictable interaction profile. Your prescribing psychiatrist must be involved before adding Semax.

If you have a history of mania or bipolar disorder: BDNF upregulation and dopaminergic stimulation may theoretically trigger manic episodes in susceptible individuals. The interaction is not well-studied, but the mechanism is plausible enough that anyone with a bipolar diagnosis should not start Semax without psychiatric oversight.

If you are pregnant or breastfeeding: No safety data exists in pregnant or lactating populations. Absolute contraindication.

If you have an active seizure disorder: A lowered seizure threshold is theoretically possible with neuroactive peptides that modulate neurotransmitter systems. There is no documented case linking Semax to seizures, but anyone with epilepsy or a seizure history should not start without their neurologist’s involvement.

Before You Start: Get Baseline Labs

We recommend baseline lab work before starting any peptide protocol so you and your provider can track changes. Key markers include IGF-1, fasting glucose, CBC, CMP and a thyroid panel.

Ask your provider about ordering these labs, or search for direct-to-consumer lab testing services in your area.

Lab recommendations are the same regardless of which service you use. See how we make money.

Questions for Your Provider

  1. 1Given that most Semax research is from Russian literature, how do you evaluate the evidence for prescribing it?
  2. 2What dosage and cycle length do you recommend for my specific cognitive concerns?
  3. 3Can Semax interact with any medications I’m currently taking, particularly SSRIs or stimulants?
  4. 4How will we measure whether it’s working — subjective assessment or cognitive testing?
  5. 5Where do you source your Semax, and can it be legally compounded right now?
  6. 6Would you recommend Semax alone or combined with Selank?

Find a Provider

We’re finalizing our vetted provider list. Subscribe to be notified when provider recommendations go live.

When provider links go live, we’ll disclose all affiliate relationships here. See how we make money.

Stay ahead of the FDA.

Regulatory updates as developments happen. New compound profiles weekly. No spam. No sales pitches.

Subscribe